232 related articles for article (PubMed ID: 36437506)
21. Molecular Barcode Sequencing for Highly Sensitive Detection of Circulating Tumor DNA in Patients with Esophageal Squamous Cell Carcinoma.
Hagi T; Kurokawa Y; Takahashi T; Saito T; Yamashita K; Tanaka K; Makino T; Yamasaki M; Nakajima K; Mori M; Doki Y
Oncology; 2020; 98(4):222-229. PubMed ID: 31846968
[TBL] [Abstract][Full Text] [Related]
22. Somatic mutations in plasma cell-free DNA are diagnostic markers for esophageal squamous cell carcinoma recurrence.
Ueda M; Iguchi T; Masuda T; Nakahara Y; Hirata H; Uchi R; Niida A; Momose K; Sakimura S; Chiba K; Eguchi H; Ito S; Sugimachi K; Yamasaki M; Suzuki Y; Miyano S; Doki Y; Mori M; Mimori K
Oncotarget; 2016 Sep; 7(38):62280-62291. PubMed ID: 27556701
[TBL] [Abstract][Full Text] [Related]
23. Post-radiation circulating tumor DNA as a prognostic factor in locally advanced esophageal squamous cell carcinoma.
Jia R; Zhao CH; Li PS; Liu RR; Zhang Y; Chen HE; Chang LP; Gong YH; Guan YF; Yi X; Xu JM
Oncol Lett; 2021 Jan; 21(1):68. PubMed ID: 33365079
[TBL] [Abstract][Full Text] [Related]
24. Comparison of salvage chemoradiation versus salvage surgery for recurrent esophageal squamous cell carcinoma after definitive radiochemotherapy or radiotherapy alone.
Chen Y; Lu Y; Wang Y; Yang H; Xia Y; Chen M; Song H; Li T; Li D; Wang J; Li S; Wang J
Dis Esophagus; 2014; 27(2):134-40. PubMed ID: 23088212
[TBL] [Abstract][Full Text] [Related]
25. Tumour-agnostic circulating tumour DNA analysis for improved recurrence surveillance after resection of colorectal liver metastases: A prospective cohort study.
Øgaard N; Reinert T; Henriksen TV; Frydendahl A; Aagaard E; Ørntoft MW; Larsen MØ; Knudsen AR; Mortensen FV; Andersen CL
Eur J Cancer; 2022 Mar; 163():163-176. PubMed ID: 35074652
[TBL] [Abstract][Full Text] [Related]
26. Evaluating the optimal re-irradiation dose for locally recurrent esophageal squamous cell carcinoma after definitive radiotherapy.
Xu X; Wang Z; Jiang S; Shang Y; Wu Y
Radiat Oncol; 2019 Nov; 14(1):191. PubMed ID: 31684983
[TBL] [Abstract][Full Text] [Related]
27. Extended-field radiotherapy for locally advanced cervical cancer.
Thamronganantasakul K; Supakalin N; Kietpeerakool C; Pattanittum P; Lumbiganon P
Cochrane Database Syst Rev; 2018 Oct; 10(10):CD012301. PubMed ID: 30362204
[TBL] [Abstract][Full Text] [Related]
28. Real-world management and outcomes of older patients with locally advanced esophageal squamous cell carcinoma: a multicenter retrospective study.
Saito Y; Hamamoto Y; Hirata K; Yamasaki M; Watanabe M; Abe T; Tsubosa Y; Hamai Y; Murakami K; Bamba T; Yoshii T; Tsuda M; Watanabe M; Ueno M; Kitagawa Y
BMC Cancer; 2023 Mar; 23(1):283. PubMed ID: 36978040
[TBL] [Abstract][Full Text] [Related]
29. Genome-wide and size-based cell-free DNA indices as predictive biomarkers for locally advanced esophageal squamous cell carcinoma treated with preoperative or definitive chemoradiotherapy.
Kim EJ; Im HS; Lee J; Cho EH; Kim YH; Kim HR; Kim JH; Park SR
Curr Probl Cancer; 2021 Jun; 45(3):100685. PubMed ID: 33342577
[TBL] [Abstract][Full Text] [Related]
30. Salvage endoscopic resection (ER) after chemoradiotherapy for esophageal squamous cell carcinoma: What are the risk factors for recurrence after salvage ER?
Hombu T; Yano T; Hatogai K; Kojima T; Kadota T; Onozawa M; Yoda Y; Hori K; Oono Y; Ikematsu H; Fujii S
Dig Endosc; 2018 May; 30(3):338-346. PubMed ID: 29106753
[TBL] [Abstract][Full Text] [Related]
31. Unrevealing the therapeutic benefits of radiotherapy and consolidation immunotherapy using ctDNA-defined tumor clonality in unresectable locally advanced non-small cell lung cancer.
Yang Y; Wang J; Wang J; Zhao X; Zhang T; Yang Y; Pang J; Ou Q; Wu L; Xu X; Xu K; Zhao J; Bai N; Yang P; Wang S; Wang L; Bi N
Cancer Lett; 2024 Feb; 582():216569. PubMed ID: 38101608
[TBL] [Abstract][Full Text] [Related]
32. ctDNA-based detection of molecular residual disease in stage I-III non-small cell lung cancer patients treated with definitive radiotherapy.
Lebow ES; Shaverdian N; Eichholz JE; Kratochvil LB; McCune M; Murciano-Goroff YR; Jee J; Eng J; Chaft JE; Kris MG; Kalashnikova E; Feeney J; Scalise CB; Sudhaman S; Palsuledesai CC; Malhotra M; Krainock M; Sethi H; Aleshin A; Liu MC; Shepherd AF; Wu AJ; Simone CB; Gelblum DY; Johnson KA; Rudin CM; Gomez DR; Razavi P; Reis-Filho JS; Isbell JM; Li BT; Rimner A
Front Oncol; 2023; 13():1253629. PubMed ID: 37795442
[TBL] [Abstract][Full Text] [Related]
33. Endoscopic resection as an independent predictive factor of local control in patients with T1bN0M0 esophageal squamous cell carcinoma treated with chemoradiotherapy: a retrospective study.
Miyazaki T; Myojin M; Hosokawa M; Aoyama H; Okahara S; Takahashi H
Radiat Oncol; 2022 Jan; 17(1):11. PubMed ID: 35057830
[TBL] [Abstract][Full Text] [Related]
34. Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial.
Radovich M; Jiang G; Hancock BA; Chitambar C; Nanda R; Falkson C; Lynce FC; Gallagher C; Isaacs C; Blaya M; Paplomata E; Walling R; Daily K; Mahtani R; Thompson MA; Graham R; Cooper ME; Pavlick DC; Albacker LA; Gregg J; Solzak JP; Chen YH; Bales CL; Cantor E; Shen F; Storniolo AMV; Badve S; Ballinger TJ; Chang CL; Zhong Y; Savran C; Miller KD; Schneider BP
JAMA Oncol; 2020 Sep; 6(9):1410-1415. PubMed ID: 32644110
[TBL] [Abstract][Full Text] [Related]
35. Minimal residual disease guided radical chemoradiotherapy combined with immunotherapy after neoadjuvant immunochemotherapy followed by adjuvant immunotherapy for esophageal squamous cell cancer (ECMRD-001): a study protocol for a prospective cohort study.
Wang H; Zhang X; Zhao X; Song C; Deng W; Shen W
Front Immunol; 2023; 14():1330928. PubMed ID: 38274807
[TBL] [Abstract][Full Text] [Related]
36. Exosome-derived miR-339-5p mediates radiosensitivity by targeting Cdc25A in locally advanced esophageal squamous cell carcinoma.
Luo A; Zhou X; Shi X; Zhao Y; Men Y; Chang X; Chen H; Ding F; Li Y; Su D; Xiao Z; Hui Z; Liu Z
Oncogene; 2019 Jun; 38(25):4990-5006. PubMed ID: 30858545
[TBL] [Abstract][Full Text] [Related]
37. Circulating tumor DNA serial monitoring of relapse and responses to tislelizumab immunotherapy as second‑line monotherapy for metastatic esophageal squamous cell carcinoma: A prospective study.
He Q; Shi X; Yan J; Wu M; Gu C; Yu X
Mol Clin Oncol; 2024 Apr; 20(4):29. PubMed ID: 38414510
[TBL] [Abstract][Full Text] [Related]
38. Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer.
Gale D; Heider K; Ruiz-Valdepenas A; Hackinger S; Perry M; Marsico G; Rundell V; Wulff J; Sharma G; Knock H; Castedo J; Cooper W; Zhao H; Smith CG; Garg S; Anand S; Howarth K; Gilligan D; Harden SV; Rassl DM; Rintoul RC; Rosenfeld N
Ann Oncol; 2022 May; 33(5):500-510. PubMed ID: 35306155
[TBL] [Abstract][Full Text] [Related]
39. Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer.
Tie J; Cohen JD; Wang Y; Christie M; Simons K; Lee M; Wong R; Kosmider S; Ananda S; McKendrick J; Lee B; Cho JH; Faragher I; Jones IT; Ptak J; Schaeffer MJ; Silliman N; Dobbyn L; Li L; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
JAMA Oncol; 2019 Dec; 5(12):1710-1717. PubMed ID: 31621801
[TBL] [Abstract][Full Text] [Related]
40. Clinical outcomes and toxicities of locally advanced esophageal squamous cell carcinoma patients treated with early thoracic radiation therapy after induction chemotherapy.
Qiu J; Lin H; Yu Y; Ke D; Li H; Zheng H; Zheng Q; Wang Z; Lin M; Yang J; Liu L; Zhang M; Liu T; Wu Y; Li J; Lai J
Int J Clin Oncol; 2023 Apr; 28(4):550-564. PubMed ID: 36735115
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
